Antiretroviral Activity of the Anti‐CD4 Monoclonal Antibody TNX‐355 in Patients Infected with HIV Type 1
The Journal of Infectious Diseases2004Vol. 189(2), pp. 286–291
Citations Over TimeTop 10% of 2004 papers
Daniel R. Kuritzkes, Jeffrey M. Jacobson, William G. Powderly, Eliot Godofsky, Edwin DeJesus, Frances F Haas, Keith A. Reimann, Jeffrey L. Larson, Patrice O. Yarbough, Valentin Curt, William Shanahan
Abstract
Single doses of TNX-355 reduced plasma HIV-1 RNA loads and increased CD4+ T cell counts in HIV-infected subjects. The further assessment of therapeutic potential awaits data from longer-duration trials.
Related Papers
- → Sensitivity and specificity of dosing alerts for dosing errors among hospitalized pediatric patients(2014)29 cited
- → Efficacy of nivolumab four-weekly dosing schedule based on body weight(2019)10 cited
- → Approaches to maintenance dosing during oral immunotherapy(2022)2 cited
- → The Impact of Role of Pharmacists in Renal Dosage Adjustment Program on Renal Drug Dosing Errors: A Quasi-Experimental Study(2021)1 cited
- → Pharmacokinetics‐Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease(2019)1 cited